Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polymorphism at codon 213 within the p53 gene.

D Carbone1, I Chiba, T Mitsudomi

  • 1Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20889-5105.

Oncogene
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probing nuclear interactions à la Rutherford: insights on <sup>4</sup>He from α scattering.

Nature communications·2026
Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026
Same author

Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Giant valley-Zeeman coupling in the surface layer of an intercalated transition metal dichalcogenide.

Nature materials·2023
Same author

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.

ESMO open·2022
Same author

Association of Daily Physical Activity with Disability in Community-Dwelling Older Adults With/Without Chronic Kidney Disease.

The journal of nutrition, health & aging·2022
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
Same journal

Correction: SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle.

Oncogene·2026
See all related articles

A rare p53 gene polymorphism was found in 3.2% of lung and breast cancer patients. This silent alteration can be mistaken for a mutation during genetic analysis, highlighting the need for careful screening.

Area of Science:

  • Genetics
  • Molecular Biology
  • Oncology

Background:

  • The p53 gene is a critical tumor suppressor.
  • Genetic variations in p53 can impact cancer development and detection.
  • Accurate identification of p53 alterations is crucial for cancer diagnostics.

Purpose of the Study:

  • To report a rare polymorphism in the p53 gene.
  • To assess the frequency of this polymorphism in cancer DNA.
  • To highlight potential diagnostic challenges posed by this variant.

Main Methods:

  • DNA analysis of lung and breast cancer samples.
  • Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis targeting the p53 gene.
  • Comparison of tumor DNA with normal tissue DNA.

Related Experiment Videos

Main Results:

  • A rare silent polymorphism (CGA to CGG) was identified at codon 213 of the p53 gene.
  • This polymorphism was detected in 3.2% (6 out of 189) of analyzed lung and breast cancer DNAs.
  • The identified polymorphism resulted in the loss of a TaqI restriction enzyme site.

Conclusions:

  • The identified p53 polymorphism is a rare genetic alteration.
  • This variant can be misidentified as a pathogenic mutation using standard mutation screening techniques.
  • Comparison with normal tissue DNA is essential to correctly distinguish this polymorphism from true mutations.